bioRxivImmunologyPreprint
Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries
M. D. Beasley, S. Aracic, F. M. Gracey, R. Kannan, A. Masarati, S. R. Premaratne, M. Udawela, R. E. Wood, S. Jabar, N. Church, T.-K. Le, D. Makris, B. K. McColl, B. R. Kiefel
Abstract
Antibodies with high affinity against the receptor binding domain (RBD) of the SARS-CoV-2 S1 ectodomain were identified from screens using the Retained Display (ReD) platform employing a 1 x 1011 clone single-chain antibody (scFv) library. Numerous unique scFv clones capable of inhibiting binding of the viral S1 ectodomain to the ACE2 receptor in vitro were characterized. To maximize avidity, selected clones were reformatted as bivalent diabodies and monoclonal antibodies (mAb). The highest affinity mAb completely neutralized live SARS-CoV-2 virus in cell culture for four days at a concentration of 6.7 nM, suggesting potential therapeutic and/or prophylactic use. Furthermore, scFvs were identified that greatly increased the interaction of the viral S1 trimer with the ACE2 receptor, with potential implications for vaccine development.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
F. Bertoglio, D. Meier, … M. Hust·bioRxiv·Jun 5, 2020
- Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models
W. Li, A. Drelich, … D. S. Dimitrov·bioRxiv·May 13, 2020
- Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection
- A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations
F. Bertoglio, V. Fühner, … M. Hust·Cell ReportsPeer-reviewed·Jul 1, 2021
- Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy
- Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization
B. Wang, D. Asarnow, … C.-I. Wang·bioRxiv·Jul 14, 2020